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Abstract
Background: Venous leg ulcers (VLUs) are expensive to treat and impair quality of life of affected individuals.
Although improved healing and reduced recurrence rates have been observed following the introduction of
evidence-based guidelines, a significant evidence-practice gap exists. Compression is the recommended first-line
therapy for treatment of VLUs but unlike many other developed countries, the Australian health system does not
subsidise compression therapy. The objective of this study is to estimate the cost-effectiveness of guideline-based
care for VLUs that includes public sector reimbursement for compression therapy for affected individuals in Australia.
Methods: A Markov model was designed to simulate the progression of VLU for patients receiving guideline-based
optimal prevention and treatment, with reimbursement for compression therapy, and then compared to usual care in
each State and Territory in Australia. Model inputs were derived from published literature, expert opinion, and
government documents. The primary outcomes were changes to costs and health outcomes from a decision to
implement guideline-based optimal care compared with the continuation of usual care. Sensitivity analyses were
performed to test the robustness of model results.
Results: Guideline-based optimal care incurred lower total costs and improved quality of life of patients in all
States and Territories in Australia regardless of the health service provider. We estimated that providing compression
therapy products to affected individuals would cost the health system an additional AUD 270 million over 5 years but
would result in cost savings of about AUD 1.4 billion to the health system over the same period. An evaluation of
unfavourable values for key model parameters revealed a wide margin of confidence to support the findings.
Conclusions: This study shows that guideline-based optimal care would be a cost-effective and cost-saving strategy to
manage VLUs in Australia. Results from this study support wider adoption of guideline-based care for VLUs and the
reimbursement of compression therapy. Other countries that face similar issues may benefit from investing in guideline-
based wound care.
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Background
The prevalence of venous leg ulcers (VLUs) increases with
age and although there are no recent or nationwide stud-
ies in Australia, prevalence is estimated at 0.33% in people
aged over 60 years based on a study in Western Australia
from the early 1990s [1]. However, this common and
recurrent problem has likely increased in recent years with
population ageing. VLUs are expensive to treat and re-
quire extensive health care resources such as frequent
dressing changes by health professionals. The average cost
of VLU treatment per patient in 2012–13 in Australia was
estimated to be AUD 8106 [2]. Patients with VLUs also
experience impaired quality of life (QoL) as a result of
significant pain, restricted mobility and limited ability to
work [3].
In Australia, the Australian and New Zealand Clinical
Practice Guideline for Prevention and Management of
Venous Leg Ulcers presents a comprehensive review of
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the assessment, diagnosis, management and prevention of
VLUs based on best available evidence [4]. Even though
improved healing and reduced recurrence rates have been
observed following the introduction of evidence-based
guidelines [5], a significant evidence-practice gap exists.
Although the guideline recommends the use of compres-
sion therapy for both treatment and prevention of VLUs,
studies found that 40–60% of VLUs in Australia did not
receive adequate compression therapy [6, 7]. This gap is
attributable to lack of information, skills and reimburse-
ment [8, 9]. Medicare, Australia’s universal health insur-
ance scheme, funded by the Australian Government,
reimburses health care provided by general practitioners
(GPs), medical specialists and nurse practitioners outside
hospital as per the Medicare Benefits Schedule (MBS)
[10]. Unlike many other developed countries, in Australia,
compression therapy is not subsidised through MBS or
Pharmaceutical Benefits Scheme (PBS) [11] which lists the
medical services and medicines subsidized by the Austra-
lian Government. Only veterans who have served in the
Australian Defence Force covered by the Repatriation
Schedule of Pharmaceutical Benefits (RPBS) receive sub-
sidies for compression bandages. The out-of-pocket costs
for VLU patients over 60 years old have been estimated at
AUD 27.5 million per year in total [2].
There is also little evidence on whether guideline-based
care for VLU is cost-effective and represents good value
for money in Australia. One study in Australia recently
conducted an economic evaluation of compression
therapy for VLUs [2]. The study modelled treatment path-
ways for VLUs and determined the expected cost of treat-
ment per patient and per wound for compression and
non-compression therapies. Results from the model dem-
onstrated that patients undergoing compression therapy
would incur fewer costs than those treated without com-
pression therapy. Unfortunately, the study did not include
other important recommendations of evidence-based care.
Recurrence was not taken into account in the model,
hence prevention of VLUs was not considered, and it was
assumed that patients treated with compression therapy
would not experience complications that required
hospitalisation. The total costs of managing VLUs may
therefore have been underestimated in the compression
group.
In response to the need for evidence on cost-effectiveness,
we conducted a comprehensive economic evaluation of
guideline-based care for VLUs by State and Territory in
Australia drawing on multiple data sources including data
from previous economic evaluations. The aim was to esti-
mate the cost-effectiveness of guideline-based optimal pre-
vention and treatment of VLUs in Australia that includes
reimbursement for compression therapy for patients with an
active ulcer and patients with a healed ulcer and history of
VLU to prevent recurrence.
Methods
This economic evaluation conforms to the guidelines out-
lined in the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement [12], with regard
to reporting of methods and results (Additional file 1: Table
S11).
Description of two competing systems of care for VLUs
Optimal care
Optimal care refers to a situation where all individuals
with VLUs receive guideline-based care with appropriate
MBS and PBS reimbursement linked to compression
therapy provided by accredited wound care providers
assuming 100% adherence. However, it is possible that
even with economic incentives and encouragement,
some patients will never consistently wear compression
therapy as required and others will be adherent without
these incentives. Clinical practice under optimal care
follows the Australian and New Zealand Clinical Practice
Guideline which has a flow chart of evidence-based
recommendations including compression therapy for the
prevention and management of VLUs [4]. The key
elements of optimal care are summarised in Additional
file 1: Table S1.
Optimal wound care service delivery
We assumed that optimal wound care services could be
delivered through either: Option 1) specialist wound
clinics led by nurse practitioners with wound expertise
together with a team of allied health professionals and
specialists; or Option 2) GPs, community nursing ser-
vices and outpatient clinics by clinicians trained in
evidence-based wound care.
Usual care
Usual care refers to a situation where individuals do not re-
ceive all the components of guideline-based care listed
under optimal care. Since a small proportion of Australians
are currently receiving compression therapy we tried to
model a situation where usual care would also include a
proportion of patients receiving compression therapy but
with partial adherence and no reimbursement hence incur-
ring substantial out-of-pocket costs. Since different funding,
reimbursement arrangements and cost structures apply to
different health care providers in different States and Terri-
tories in Australia, patient out-of-pocket payments for
wound care also vary depending on these arrangements
and structures (Additional file 1: Table S3).
Markov model simulation
Building on our previous model [13], a decision-analytic
Markov model was developed to assess the cost-effectiveness
of guideline-based optimal care for VLUs in each of the eight
States and Territories in Australia (New South Wales
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(NSW), Victoria (VIC), Queensland (QLD), South Australia
(SA), Western Australia (WA), Northern Territory (NT),
Tasmania (TAS), and Australian Capital Territory (ACT)). In
this study, five mutually exclusive health states were
identified for the model: ‘No VLU’, ‘Unhealed VLU’, ‘Healed’,
‘Complicated VLU with hospitalisation’ and ‘Death’ and
individuals can transit between these states (Fig. 1). One
advantage of Markov models is that recurrent events over
time can be modelled [14]. Thus, in our model, individuals
could experience more than one VLU or hospitalisation.
The model ran on fortnightly cycles for a total of
130 cycles or 5 years. A time horizon of 5 years was
chosen to incorporate long-term recurrence. Since VLU
mainly affects the elderly population, the target popula-
tion entering the model would be the general population
aged 60 years and over in each State and Territory. At
cycle 0, 0.33% of the population would be distributed to
‘Unhealed VLU’ state to represent current prevalence of
VLUs. The remaining population would enter the model
from ‘No VLU’ state referring to no previous or current
VLU in this population but at risk of developing VLUs.
After one cycle (i.e. a fortnight), people in ‘No VLU’
state could develop an ulcer and enter ‘Unhealed VLU’
state, remain in ‘No VLU’ state or die from all causes.
Meanwhile, those with VLUs could either become
‘Healed’, develop ‘Complicated VLU with hospitalisation’,
remain in the ‘Unhealed VLU’ state or die of all causes.
Those patients that moved to the ‘Healed’ state would be
at risk of recurrence, and likely to develop another VLU
and return to ‘Unhealed VLU’ state in the next cycle. For
those hospitalised, we assumed that all would be dis-
charged from hospital after one cycle (a fortnight) or die
of all causes. To take into account the aging population
in Australia and obtain a more real-world estimate, the
general population that gradually turns 60 was added to
the ‘No VLU’ state cycle by cycle as new at-risk
population. The average population growth for popula-
tion aged 60 years and over was calculated using Austra-
lian Bureau of Statistics data [15] (as explained in more
detail in the Additional file 1). The growth rate was not
applied to cohorts in other health states.
The transitions between states depended on transition
probabilities (i.e. incidence, probability of healing, prob-
ability of recurrence, probability of hospitalisation, prob-
ability of death). Costs and health outcomes (expressed in
quality-adjusted life years (QALYs)) associated with each
health state per cycle were incorporated into the model
and were accumulated over 130 cycles. Future costs and
QALYs were discounted at 5% in baseline analyses in line
with Australian government guidelines [16, 17]. All ana-
lyses were conducted using Microsoft Excel 2010.
Data used for the model
Transition probabilities
A comprehensive review of literature was conducted to
source transition probabilities for the model. The inci-
dence of VLU in older persons has not been well estab-
lished in Australia. We used an annual incidence rate of
1.2 cases per 100 person-years from a UK study where
the incidence of VLUs among people aged 65 years and
older was reported [18] and applied this to the Austra-
lian population as summarised in Table 1.
The probability of ulcer healing in the optimal care
group and usual care group were obtained from Harrison
et al. [19]. In the Harrison et al. [19] study in Canada,
3-month healing rates for VLUs more than doubled
between the year before (22.8% [13/57]) and after (58.7%
[64/109]) implementation of an evidence-based service. In
the same study, use of compression for VLUs increased
from 43.9% (25/57) in the old model of care to 85.3% (93/
109) after implementation of the new model. In a small
study in Queensland, Edwards et al. [5] reported that 84%
Fig. 1 Markov model structure for assessing the cost-effectiveness of guideline-based optimal care for VLUs
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of patients with a VLU were treated with compression
therapy following admission to a specialist wound clinic
while only 6.3% (2 of 32) of patients with a venous leg
ulcer were receiving compression on admission to the
clinic and a total of 11% had been treated with compres-
sion therapy at any time in the previous 12 months prior
to admission. Healing was significantly associated with im-
plementation of compression therapy with 63% (n = 20) of
the participants with venous leg ulcers healed by 3 months,
although this study did not report healing rates prior to
admission to the specialist wound clinic. Since Edwards et
al. [5] reported similar healing rates with implementation
of evidence-based services as Harrison et al. [19], and the
two studies reported similar use of compression therapy
after implementation of evidence-based care, healing rates
from the Harrison et al. [19] study were used in this ana-
lysis for optimal care and usual care as we were assuming
that about 50% of patients in usual care group receive
compression therapy.
Recurrence rates from Edwards et al. [5] and Finlayson
et al. [20] were used to inform probability of ulcer recur-
rence in the optimal care group and usual care group,
respectively. In the absence of local data, probabilities of
hospitalisation due to VLU complications in the optimal
care group and usual care group were derived from
studies by Barwell et al. [21] and Walker et al. [22], re-
spectively. All admissions to hospital were assumed to
occur in public hospitals as Independent Hospital Pri-
cing Authority (IHPA) mainly collects data from public
hospitals [23]. For individuals that transited to or
remained in ‘Unhealed’ state, we assumed that 5% of
them would have infected VLU if they received optimal
care and 10% of them would have an infection if they re-
ceived usual care [24]. Since there is insufficient evi-
dence for an increased risk of mortality with VLU,
all-cause mortality rates for people aged 60 years and
over were calculated using aged-specific deaths and
age-specific population by State and Territory from the
Australian Bureau of Statistics dataset [15]. Yearly and
monthly probabilities were then transformed to fort-
nightly probabilities [14]. Because the probabilities of
moving between states in each cycle must sum up to 1,
the probability of staying in a state was one minus the
sum of the probabilities of leaving the state.
Resources use and costs
Costs associated with health states and transitions in the
Markov model were measured in 2015 Australian dol-
lars. This study was conducted from a partial societal
perspective. Patients’ out-of-pocket costs were calcu-
lated. But costs of lost productivity were not considered
in this study as we expected that most patients aged
60 years and over would be retired. We also did not in-
clude the cost of education and training of health pro-
fessionals in evidence-based practice in optimal care
Options 1 and 2. Resource use in usual care group and
optimal care group is summarised in Table 2 with details
and assumptions presented in the Additional file 1.
QALYs
QoL utility scores for ‘Unhealed VLU’ and ‘Healed’ state
were sourced from lglesias et al. [25]. As we could not
Table 1 Markov model inputs
Variables Value References
Transition probabilitiesa
Usual care
Probability of healing (3-month) 0.2281 [19]
Probability of recurrence (annual) 0.5574 [20]
Probability of hospitalisation
(5-year)
0.24 [22]
Optimal care
Probability of healing (3-month) 0.5872 [19]
Probability of recurrence (annual) 0.2222 [5]
Probability of hospitalisation
(annual)
0.0116 [21]
VLU Incidence rate (annual) 0.0121 [18]
All-cause mortality rate (annual) 0.0282 Calculated from
ABS data [15]
Proportion of unhealed ulcers with
infection
Usual care 10% [24]
Optimal care 5% [24]
Cost itemsb
GP AUD 71.70 MBS item 36
Nurse practitioner AUD 58.55 MBS item
82215
Vascular surgeon AUD 85.55 MBS item 104
Community nurse hourly
wage rate
AUD 24.74–37.05 [31–38]
Ankle-brachial pressure index
(ABPI) assessment
AUD 63.74 MBS item
11610
Pathology test AUD 33.75 MBS item
69306
Compression bandage AUD 51.5 Retail price
Compression stocking AUD 97.75 Retail price
Complicated VLU with
hospitalisation
AUD 18,331.60 [23]
Quality of life utility score
Healed VLU 0.75 [25]
Unhealed VLU 0.64 [25]
Complicated VLU with
hospitalisation
0.54 calculated
aYearly or monthly probabilities were transformed to fortnightly probabilities
by the formula: tp = 1 – (1 - tpt)
1/t [14]
bCosts for health states by State and Territories in Australia are presented in
Additional file 1 Table S4
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identify information on the QoL of patients hospitalised
due to VLUs, we assumed a decrement of 0.1 utility
score for ‘Complicated VLU with hospitalisation’ state as
done by one National Institute for Health and Care
Excellence guideline [26]. QALYs were calculated by
multiplying the utility score by the amount of time spent
in that health state.
Model outputs
The primary outcome measures analysed in the model
were the expected total costs and QALYs associated with
optimal care versus usual care in each State and Territory
over 5 years. Total costs were separated into costs covered
by the health system and out-of-pocket costs. The Austra-
lian government and State and Territory government
share of the health system costs was estimated. Expected
costs of compression therapy were calculated for both
groups. Assuming that public hospitals are funded by both
State and Territory governments (60%) and the Australian
government (40%) [27] and MBS and PBS costs as well as
cost of products for compression therapy under optimal
care are covered by the Australian government, we also
calculated the cost savings to State and Territory govern-
ments and the Australian government respectively.
Deterministic sensitivity analysis
There is always uncertainty in the estimation of model
inputs of interest such as healing rate and hospitalisation
rate. One-way sensitivity analysis was therefore con-
ducted where model inputs were varied between a low
value and high value using a uniform distribution and
corresponding model outputs were recorded. The model
input that had the greatest impact on the outcomes was
evaluated further in a scenario analysis.
Probabilistic sensitivity analysis
Uncertainty around model inputs was quantified using
probabilistic sensitivity analysis (PSA) to give the
decision maker insight into the probability that a change
to practice will be cost-effective. Statistical distributions
were used to describe variability in the model inputs.
Transition probabilities and quality of life utility scores
were assigned beta distributions. Gamma distributions
were used for cost parameters to reflect the skew typic-
ally found in cost data. 10,000 Monte Carlo simulations
were performed for PSA. In each simulation, the model
parameters took random values from the fitted distribu-
tion, and the economic outcomes of change to costs
(ΔC) and change to health benefits or QALYs (ΔE) were
calculated. Net monetary benefit (NMB) was then calcu-
lated by NMB=ΔE* λ - ΔC where λ is the decision maker’s
maximum willingness-to-pay threshold for an additional
unit of health benefit gain. A value of $64,000 per QALY
was used for willingness-to-pay in this study, in line with
research in an Australian setting [28]. NMB greater than 0
indicates that optimal care is cost-effective in this simula-
tion. The results of 10,000 simulations were presented
using a cost-effectiveness plane. The probability that opti-
mal care was cost-effective at certain willingness-to-pay
thresholds was derived by counting the number of times
out of 10,000 that NMB was greater than 0 and sum-
marised in cost-effectiveness acceptability curves.
Results
Baseline analysis
By the end of 2020, we estimated that there would be
over 300,000 people affected by VLU in Australia which
would include new and existing cases over that period as
well as individuals with a healed ulcer that have a history
of VLU. This should not be expressed as the number of
existing cases at the end of 5 years as it does not take
into account mortality or healed cases over that 5-year
period. Estimated number of people affected by VLU
and hospitalisation in each State and Territory is pre-
sented in Additional file 1: Table S5. Number of
Table 2 Summary of resource use in usual care group and optimal care group
Usual care Optimal care (Option 1) Optimal care (Option 2)
Healed VLU No additional care • Clinic assessment by nurse practitioner
every 3 months
• Compression stocking every 3 months
• Clinic assessment by GP every
3 months
• Compression stocking every
3 months
Unhealed VLU • One-off assessment by GP
• Clinic visits to GP or community
nurse or outpatient clinic twice a week
• Dressings change twice a week
• High compression therapy prescribed
to 50% of patients
If infected
• Pathology test every week
• systemic antibiotics
• One-off ABPI or vascular assessment and
assessment by nurse practitioner and
vascular surgeon
• Clinic visits to nurse practitioner once
a week
• Dressings change every week
• High compression therapy prescribed
to everyone
If infected
• One-off pathology test
• Debridement once a week
• Systemic antibiotics
• One-off ABPI and GP assessment
• Clinic visits to GP or community nurse
or outpatient clinic once
a week
• Dressings change every week
• High compression therapy
prescribed to everyone
If infected
• One-off pathology test
• Debridement once a week
• Systemic antibiotics
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hospitalisations avoided through optimal care over
5 years was estimated at 21,677 nationwide.
In optimal care service delivery Option 1 where optimal
care was provided by specialist nurse practitioners, the
expected total cost for all affected persons over 5 years was
over AUD 1.2 billion under optimal care and over AUD 2.8
billion under usual care (Table 3). In addition to lowered
costs, the society would witness improved quality of life
among patients managed by optimal care. Total costs were
broken down to costs borne by the health system and
out-of-pocket costs by patients. Following guideline-based
optimal care would always be a cost-saving strategy for the
health system. Although there are currently no specific
MBS item numbers for compression therapy, under usual
care, the health system is already paying an estimated 270
million for compression products indirectly. Under optimal
Table 3 Baseline outcomes for all affected persons over 5 years in Australia (optimal care versus usual care)c
Option 1 Option 2
Total costs in usual care group $2,831,006,652 $2,831,006,652
Total costs in optimal care group $1,200,427,937 $1,126,566,791
Total incremental costs -$1,630,578,715 -$1,704,439,861
Health system costs in usual care group $2,516,869,902 $2,516,869,902
Health system costs in optimal care group $1,128,856,145 $1,093,241,400
Incremental costs -$1,388,013,757 -$1,423,628,502
Costs by Australian government in usual care group $2,298,900,749 $2,298,900,749
Costs by Australian government in optimal care group $1,114,692,967 $1,079,078,223
Incremental costs -$1,184,207,781 -$1,219,822,526
Costs by State and Territory government in usual care group $217,969,153 $217,969,153
Costs by State and Territory government in optimal care group $14,163,177 $14,163,177
Incremental costs -$203,805,976 -$203,805,976
Out-of-pocket costs in usual care group $314,136,750 $314,136,750
Out-of-pocket costs in optimal care group $71,571,792 $33,325,391
Incremental costs -$242,564,957 -$280,811,359
Total costs of compression products in usual care groupa $487,379,273 $487,379,273
Total costs of compression products in optimal care groupb $539,765,074 $539,765,074
Incremental costs $52,385,801 $52,385,801
Costs of compression products in usual care group indirectly covered by health system $271,197,256 $271,197,256
Total costs of compression products in optimal care group covered by health system $539,765,074 $539,765,074
Incremental costs $268,567,818 $268,567,818
Costs of other dressings in usual care group $37,875,018 $37,875,018
Costs of other dressings in optimal care group $68,758,106 $68,758,106
Incremental costs $30,883,088 $30,883,088
Total QALYs in usual care group 476,090 476,090
Total QALYs in optimal care group 504,431 504,431
Incremental QALYs 28,341 28,341
aTotal costs of compression products in usual care group were covered by out-of-pocket expenditure and government’s funding to health professionals
bCosts of compression products in optimal care group were covered by Australian government
cCosts were measured in 2015 Australian dollars. Baseline outcomes by State and Territory are summarised in Additional file 1 Tables S6 and S7. Costs per person
and QALY per person could not be calculated by dividing the total by the number of affected persons as not all affected persons received treatment and
prevention for the entire 5 years in this model. By the end of 2020, patients who developed VLUs in 2016 would incur more costs associated with treatment and
prevention than those who developed VLUs in 2017. Expected costs and QALYs per person over 5 years if the person received treatment and prevention for
5 years are summarised in Additional file 1: Tables S8 and S9
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care, funding consumables for compression therapy for
treatment of patients with existing VLUs and prevention to
patients with a history of VLUs would cost the Australian
government an additional 270 million over 5 years. The
cost savings to the Australian government through reduced
health service utilisation as a result of faster healing of
wounds, ulcers avoided and hospitalisations avoided would
be about AUD1.2 billion (85% of cost-savings to the health
system) and to state and territory governments about AUD
200 million over 5 years through reductions in hospitalisa-
tions due to complications.
The optimal care service delivery Option 2 (guideline--
based wound care delivered by trained GP, community
nurses, outpatient clinics) analysis showed similar results to
Option 1. Guideline-based optimal care is a cost-effective
and cost-saving strategy as it costs less than usual care and
generated more QALYs even after factoring in the add-
itional costs of compression therapy under guideline-based
optimal care. The costs borne by the health system under
second option of optimal care service delivery were slightly
lower than under Option 1 (specialist wound clinic with
nurse practitioner) since a proportion of care under Option
2 (GP, community nursing, outpatient clinics) was provided
by community nurses at lower costs. Patients also incurred
lower out-of-pocket costs when receiving optimal care at
GP clinic, community or outpatient clinics compared with
specialist clinics as patients would receive subsidies for
other consumables used according to Additional file 1:
Table S3. Nevertheless, cost savings to health system are
similar at around AUD 1.4 billion (AUD 1.2 billion to
Australian government and AUD 200 million to State and
Territory) with optimal care for VLU.
Deterministic sensitivity analysis
Results of one-way sensitivity analyses under Option 1
as an example are summarised using tornado diagrams
(Figs. 2 and 3) where each bar represents one one-way
sensitivity analysis and the width of the bar shows the
extent of impact on model results. The vertical line de-
notes ICER from baseline analysis. The tornado diagram
indicates that varying values of hospitalisation rate in
usual care group would greatly change the amount of
benefit gained whereas varying the probability of healing
or recurrence to less favourable values has less impact.
Scenario analysis was then conducted to test how dif-
ferent values of hospitalisation rate (per annum) in usual
care group influenced the costs and health outcomes of
optimal care compared with usual care (Table 4). The
lowest value tested was the same as hospitalisation rate
in optimal care group (1.16%). The high value of
Fig. 2 Tornado diagrams for NSW, VIC, QLD, SA (optimal care service delivery Option 1)
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probability of hospitalisation in the usual care group
was calculated using the number of VLU hospitalisa-
tions divided by the VLU population aged 60 and
over. The number of VLU hospitalisations was based
on hospitalisations associated with leg ulcer complica-
tions such as cellulitis as per Australian Refined Diag-
nosis Related Groups (AR-DRG codes J12A and J12B)
[23]. The results suggested that the higher the hospi-
talisation rate, the higher the cost savings and avoided
hospitalisations, but the analysis shows cost savings
even when using the lowest value of hospitalisation
rate.
An additional scenario analysis was conducted for
prevalence of VLUs. As there is no recent population
study of the prevalence of VLUs in Australia, it was as-
sumed that the prevalence could take values between
0.33 and 1.69% where the upper limit was the prevalence
of VLU observed in elderly population in UK [18].
Table 5 summarises the costs and health outcomes of
implementing optimal care compared with usual care in
Australia under different values of prevalence. The re-
sults suggested that optimal care was always associated
with lower costs and higher QALYs. The cost-savings
would increase as prevalence of VLU increases.
Fig. 3 Tornado diagrams for WA, NT, TAS, ACT (optimal care service delivery Option 1)
Table 4 Scenario analysis varying hospitalisation rate in usual care group (optimal care service delivery Option 1)a
Hospitalisation rate in usual care group (annual) 5.34% (Baseline) 1.16% (low) 12.36% (high)
Total costs in usual care group $2,831,006,652 $2,543,990,422 $3,340,479,326
Total costs in optimal care group $1,200,427,937 $1,200,427,937 $1,200,427,937
Total incremental costs -$1,630,578,715 -$1,343,562,485 -$2,140,051,390
Total QALYs in usual care group 476,090 476,181 475,928
Total QALYs in optimal care group 504,431 504,431 504,431
Incremental QALYs 28,341 28,249 28,503
Hospitalisations avoided over 5 years 21,677 3461 54,013
a Costs, QALYs and hospitalisations avoided were calculated for all individuals affected by VLU over 5 years in Australia
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Probabilistic sensitivity analysis
The 10,000 iterations of change to costs and health out-
comes are displayed in Fig. 4 using NSW as an example.
Each dot represents one iteration and most dots lie below
the willingness-to-pay line, which means that optimal care
has a high probability of being cost-effective when the
willingness-to-pay is AUD 64,000/QALY. The probability
of optimal care being cost-saving is about 70% when only
dots in the southeast quadrant are counted. The probabil-
ity that optimal care is cost-effective at different
willingness-to-pay thresholds is shown in Fig. 4. The ac-
ceptability curve demonstrates that optimal care is associ-
ated with high probability (around 70–99%) of being
cost-effective regardless of the willingness-to-pay value.
The results for other States and Territories are presented
in Additional file 1: Figures S1–S7.
Discussion
While an economic evaluation of compression therapy has
previously been conducted in Australia, this study breaks
new ground in its attempt to measure the full health and
economic impact of guideline-based care for VLUs by State
and Territory in Australia. The model takes into account
the growth in population aged 60+ years as well as new in-
cident VLU cases that develop over time. It includes recur-
rent ulcers and complications resulting in hospitalisations
in the model, to present a more comprehensive estimate of
the cost savings in Australia with guideline-based optimal
Table 5 Scenario analysis varying prevalence of VLUs (optimal care service delivery Option 1)a
Prevalence of VLU among 60+ 0.33% (Baseline) 0.50% 1% 1.69% [18]
Population 60+ affected with VLU at cycle 0 15,973 24,202 48,404 81,803
Total costs in usual care group $2,831,006,652 $2,954,936,472 $3,319,435,945 $3,822,445,216
Total costs in optimal care group $1,200,427,937 $1,246,526,209 $1,382,109,363 $1,569,214,116
Total incremental costs -$1,630,578,715 -$1,708,410,263 -$1,937,326,581 -$2,253,231,100
Total QALYs in usual care group 476,090 499,250 567,367 661,369
Total QALYs in optimal care group 504,431 528,959 601,099 700,653
Incremental QALYs 28,341 29,709 33,732 39,284
Hospitalisations avoided 21,677 22,620 25,394 29,221
aCosts, QALYs and hospitalisations avoided were calculated for all individuals affected by VLU over 5 years in Australia
Fig. 4 Probabilistic sensitivity analysis results in cost-effectiveness plane and cost-effectiveness acceptability curve (NSW as an example)
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prevention and treatment for VLU. The study shows that
over 5 years, optimal care will offset the costs of additional
investment in compression therapy for treatment and pre-
vention across all jurisdictions and save the health system
about AUD 1.4 billion. The two key drivers of the estimated
cost savings are reductions in healing time and rates of hos-
pitalisation to treat complications. These improvements in
quality of life for patients coupled with the reduced costs of
guideline-based care for VLUs can be said to dominate as a
prevention and treatment pathway for VLU. This study
contributed further evidence to the literature on the
cost-effectiveness of guideline-based wound management.
One strength of this study is that two options of deliver-
ing guideline-based care were considered in the analysis.
GP and community nurses have been at the forefront of
managing wounds in Australia [5], but evidence-based
care that follows official guidelines is not widely practiced
in primary care. For example, applying compression
therapy to VLUs requires additional time and expertise
from health professionals while the length of consultation
in general practice is limited. Although we did not include
this additional consultation time in our analysis, we
modelled the situation where GP and community nurses
are also capable of delivering optimal wound care. In most
jurisdictions, there are few out-of-pocket costs for
consumables in community nursing and outpatient clinics.
Specialist wound clinics, on the other hand, provide
evidence-based treatment and prevention but patients may
be expected to pay additional costs for accessing specialist
services and consumables. Results from this study indicated
that both options could be cost-saving in the long-term as
long as the health professionals are well-trained and
equipped with knowledge and skills to manage VLUs and
there is adequate reimbursement for clinician time and
consumables through the health system. Improving educa-
tion of patients and training of health professionals in
wound management with adequate reimbursement of
wound care products and services to increase uptake of
evidence-based care remains a priority in Australia.
It is important to note patients’ out-of-pocket expend-
iture when optimal care is implemented. Overall we esti-
mated that under usual care, VLU patients over 60 years
of age would pay more than AUD300 million in
out-of-pocket costs over 5 years. We estimated that the
out-of-pocket costs could be reduced substantially under
optimal care but the savings varied across jurisdictions.
Patients in Queensland and Victoria had higher savings
than other jurisdictions as a large proportion of consum-
able costs are paid by patients in these States, while
there is little expected benefit in the ACT as consumable
costs are already fully subsidised. The out-of-pocket
costs under optimal care also depended on service deliv-
ery: for Option 1 (specialist wound clinics led by nurse
practitioners) these costs (AUD72 million) are more
than double that under Option 2 (AUD35 million) where
care is provided by GPs, community nurses and out-
patient clinics. Although we assumed that compression
therapy consumables would be reimbursed by the health
system under optimal care, patients still had to pay a
small amount for medicines listed on the PBS and other
consumables not listed under PBS. In some States and
Territories such as ACT, patients actually pay more
out-of-pocket costs under optimal care (Option 1) than
usual care. The cause lies in how care is funded in each
State and Territory. According to the internet survey [2],
in the smallest territory ACT where Canberra, Australia’s
capital city is situated, patients may have out-of-pocket
costs for medicines but do not pay for dressings and other
consumables including compression bandages. Thus, even
under usual care, the out-of-pocket costs are low in ACT
and would be higher under optimal care for Option 1
where patients in specialist wound clinics may have
out-of-pocket expenses for certain consumables that
would not be incurred under Option 2 arrangements.
However, the proportion of consumables paid by patients
in different States and Territories (Additional file 1: Table
S3) reported in the internet survey [2] might not be accur-
ate due to the small sample size and low response rate.
Therefore, findings on patients’ out-of-pocket expenditure
presented in this study should be interpreted with caution.
Limitations
There are several limitations in this study. Firstly, data
on clinical effectiveness such as healing rate was sourced
from a non-Australian study, although it is reassuring
that a study in Queensland, Australia, reported similar
healing rates with implementation of evidence-based
wound care [5]. We assumed that 50% of patients in the
usual care group were receiving compression therapy
across all jurisdictions and that the same healing, recur-
rence and hospitalisation rates applied to all States and
Territories in Australia due to lack of local data. How-
ever, as the health service pathways and use of compres-
sion therapy differ between States and Territories, the
probability of healing, recurrence and hospitalisation
may also vary. We also assumed constant risk of recur-
rence over time in the absence of long-term follow up
data, and in order to avoid overestimation, we limited
the time horizon to 5 years. The model inputs can be
updated when national wound registry data become
available in Australia. Secondly, we relied on published
literature to estimate hospitalisation rate among patients
treated with optimal care. In Australia, the number of
hospitalisations attributed to VLUs can be obtained from
either International Classification of Diseases (ICD)
codes [29] or AR-DRG codes [23]. But whether patients
receive optimal care or usual care prior to hospitalisa-
tion is not known. A longitudinal cohort study that
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follows patients over time would be helpful to determine
the hospitalisation rate between treatment groups. It is
also important to note that in this analysis both optimal
care and usual care are simplified and extreme scenarios
for modelling while current practice in Australia is prob-
ably a mixture of optimal care and usual care. We found
that if usual care was taken as ongoing national practice,
the number of prevalent VLU cases and hospitalisations
would rocket as a result of increasing new cases and
non-healing cases over time. If optimal care was imple-
mented, then a great reduction in VLU-related hospital-
isation would be expected. Thirdly, in the absence of
Australian data, the annual incidence rate of VLUs
among general population aged 60 and over of 1.2 per
100 person-years was derived from a UK study where a
prevalence of 1.69% was reported [18]. In our study, we
used this incidence rate with a prevalence of 0.33% in-
stead but did not check the consistency of these epi-
demiological parameters [30]. Moreover, the prevalence
estimate of 0.33% used in the baseline analysis was
sourced from a study conducted in the 1990s and is very
likely to be an underestimate of current prevalence of
VLU. The scenario analysis showed that higher preva-
lence is associated with greater cost savings. Thus, total
cost savings to the Australian society may have been
underestimated in our baseline analysis. Fourthly, the
costs of consultation with GP, nurse practitioner and
vascular surgeon were assumed to follow the scheduled
fees listed on MBS, while in fact, patients sometimes pay
an additional fee for the consultations. Thus, the
out-of-pocket cost in this study may have been underes-
timated. Fifth, although Australian government and State
and Territory governments share the funding responsi-
bility for community nursing services [27], the propor-
tion of this share is not well documented. We assumed
that the Australian government covered all costs of com-
munity nursing services. Thus, the total costs borne by
State government may have been underestimated in this
analysis. We also assumed that all hospitalisations as a
result of VLU complications would occur in public hos-
pitals and hence health system costs may have been
overestimated and out-of-pocket costs to individuals
underestimated as some of the patients have private
health insurance and may be hospitalised for VLUs in
private hospitals. Finally, the cost-savings presented in
this study need to be interpreted with caution. Due to
lack of data on lost productivity, we had to assume
people aged 60 years and over are retired. With optimal
care, patients are expected to heal faster and have fewer
recurrent ulcers which means that there will be less lost
productivity compared with usual care. Thus, excluding
cost estimation on lost productivity could underestimate
cost-savings to society. We also assumed that under op-
timal care, compression therapy would be provided by
trained health professionals, but we did not take into ac-
count the cost of education and training of health care
providers in evidence-based wound management. The
costs of doing a full implementation of guideline-based
wound care would be higher than the costs included in
this study. As a result, the cost-savings to the health sys-
tem could be overestimated.
Conclusion
As the Australian population ages, the prevalence of VLUs
will continue to rise. While Australia prides itself in
having one of the developed world’s best health care
systems, and does very well compared to the rest of the
world in terms of health, wound management is an area
where Australia trails behind. Implementing a large-scale
change to current practice is complex and takes time, but
this study provides important evidence that adequate re-
imbursement for guideline-based services and products
would not only result in cost savings for patients and the
health system but also improve health outcomes and
quality of life for patients with VLUs. Therefore, we rec-
ommend better reimbursement of guideline-based care
for VLUs by the Australian health system. Measures could
include listing compression therapy in PBS for all affected
individuals or creating wound-specific MBS items. We
hope that this study could be of great relevance and
importance to other countries that face similar issues and
could benefit from investing in guideline-based wound
care.
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